Mirum Pharmaceuticals MIRM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Mirum Pharmaceuticals (MIRM) Business Model and Operations Summary
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Key Insights
Mirum Pharmaceuticals (MIRM) Core Market Data and Business Metrics
Latest Closing Price
$44.04Market Cap
$2.15 BillionPrice-Earnings Ratio
-23.81Total Outstanding Shares
49.01 Million SharesTotal Employees
322Dividend
No dividendIPO Date
July 18, 2019SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
989 East Hillsdale Boulevard, Suite 300, Foster City, CA, 94404
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $10.32 Million |
| Net Cash Flow From Investing Activities | $-90.13 Million |
| Net Cash Flow From Financing Activities, Continuing | $17.70 Million |
| Net Cash Flow From Financing Activities | $17.70 Million |
| Net Cash Flow From Investing Activities, Continuing | $-90.13 Million |
| Net Cash Flow, Continuing | $-62.10 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $424.49 Million |
| Diluted Average Shares | $47.52 Million |
| Other Operating Expenses | $222.27 Million |
| Operating Income/Loss | $-87.61 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Basic Earnings Per Share | $-1.85 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-89.96 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-89.96 Million |
| Other Comprehensive Income/Loss | $-2.02 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $27.01 Million |
| Accounts Payable | $14.62 Million |
| Equity Attributable To Parent | $225.64 Million |
| Noncurrent Assets | $277.97 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Assets | $370.38 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||